TL;DR CNBC

Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival

Publishing timestamp: 2024-04-09 14:42:47

Summary

FDA expanded approvals for cell therapies from Bristol Myers Squibb and Johnson & Johnson for multiple myeloma. J&J's drug Carvykti has a notable edge over Bristol Myers's treatment Abecma. Both drugs belong to CAR-T therapies and J&J's drug is expected to win the majority of the market share. Both companies are also facing supply constraints despite the new approvals.

Sentiment: NEUTRAL

Tickers: JNJ,  BMY, 

Keywords: health care industry,  johnson & johnson,  business news,  bristol-myers squibb co,  science,  biotech and pharmaceuticals, 

Source: https://www.cnbc.com/2024/04/09/healthy-returns-jj-cell-therapy-gains-edge-over-bristol-myers-rival.html